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28 Oral Presentationsaplasia. Cytogenetics revealed trisomy 8 mosaicism, present on
a BM specimen obtained pre-GTx (Blood 2007; 109:503). Our
2nd patient enrolled in January 2007. He received 5  106
CD341 cells/kg that showed 40–200U of ADA activity after trans-
duction (normal range 58–128). Over 6 months, this patient showed
a slow increase in ALC (up to 750/mcL) and lymphocyte function.
PBMC ADA activity has been up to 50U. The dAXP level has de-
creased to below 10%, levels typically seen after allogeneic BM
transplant. A 3rd patient was treated in May 2007 and received 2
 106 CD341 cells/kg with ADA activity of 7–87U. Over three
months, lymphocyte function has increased over pretreatment level.
PBMC ADA activity has been up to 24U and the dAXP levels have
decreased to less than 10%. Both patients have been off PEG-ADA
since 2 weeks pre-GTx and had mild post-GTx courses, with no
documented infection, and no need for blood products. AST and
ALT rose to 200 U/L, and then resolved, an effect attributed to
PEG-ADA withdrawal or busulfan administration. Without mye-
loid growth factors, times to neutrophil count above 500/mcL
were 36 and 45 days. These data are consistent with the positive re-
sults of GTx for ADA-SCID obtained in Milan and London and di-
rectly show that PEG-ADA withdrawal and reduced conditioning
improve the outcome of GTx for ADA-SCID. Longer follow-up
should allow us to study engraftment of cells containing vector-spe-
cific sequences and to conclude if either vector contributes more to
recovery of lymphoid immunity.69
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Relapse and NRM after allogeneic HSCT remain significant bar-
riers to success in treating very high-risk ALL. Sirolimus (SRL) has
been shown to have cytotoxic activity against human ALL at serum
levels used for immune suppression. We hypothesized that the ad-
dition of SRL to a tacrolimus (TAC)/methotrexate (MTX) GVHD
prophylaxis regimen would decrease relapse after HSCT for ALL.
This multi-institutional pilot trial included a preparative regimen
of fractionated TBI (1200 cGy), thiotepa (5 mg/kg/d 2) and cyclo-
phosphamide (60 mg/kg 2). Pts received IV TAC (start d-2, target
5–10 ng/mL), PO SRL (start d0, target 3–12 ng/mL), and IV MTX
(5 mg/m2, d1 1,13, and16 plus d1 11 for UD BM/PBSC). TAC
was tapered between d 1 42–96 for MSD and d 1 100–180 for
others. SRL was tapered over 4 wks starting 6 m after transplant.
This report includes 50 pediatric pts (med age 9 (1–21)) with
a med f/u of 17 m (5–50). Immunophenotypes included 38 B-line-
age and 12 T-lineage. Risk groups included 12 pts in high risk
(HR) CR1, 5 in HR isolated extramedullary (IEM) relapse, 8 in
very early relapsing (VER,\18 m) CR2, 6 in early relapsing (ER,
18–36 m) CR2, 10 with late relapsing (LR, $36 m) CR2, and 9 in
CR3. Stem cell sources included 22 MSD-BM, 25 UCB, and 3 UD.
Results: 2 yr EFS for the entire cohort was 72% (SE 8.1) and did
not differ by stem cell source. 2 yr EFS by risk groups is outlined in
the table below, showing better than anticipated survival in all sub-
groups. Within the HR CR2 subgroups (BM relapse\36 m from
diagnosis), T-lineage VER CR2 pts had worse 2 yr EFS compared
to B-lineage VER CR2 and B- and T-lineage ER CR2 pts (2 yr EFS
20% vs. 64%, p5 0.057). One recipient of CB failed to engraft and
a second relapsed prior to engraftment. All remaining pts engrafted
at a median of 21 (13–31), 28 (16–62), and 20 (17–21) days for MSD,
CB, and UD, respectively. aGVHD grade II-IV and III-IV oc-
curred in 40 and 21% of patients, while cGVHD occurred in
30%. NRM occurred in 5 patients (10%: 4 CB, 1 MSD). Significant
toxicities included VOD (5 pts, reversible in 3, part of fatal MSOF
in 2 in the context of bacterial (1) and viral (1) sepsis), non-fatal
HUS (2 pts), and non-fatal IPS (1 pt). In summary, SRL-based
GVHD prophylaxis after TBI/TT/Cy allogeneic HSCT results
in high rates of engraftment, low NRM, and improved 2 yr EFSin every risk group except T-lineage VER in CR2. A phase 3 trial
in the COG for ALL patients in CR2 comparing TAC/MTX
with TAC/MTX/SRL after TBI/TT/Cy allogeneic HSCT is on-
going.2 yr EFS by Risk Group
ALL Risk ALL HR ALLVER ALL ER ALL LR ALL IEMGroup CR1 CR2 CR2 CR2 ALL CR3 CR22 yr EFS (±SE) 92% (±8) 38% (±17) 60% (±22) 90% (±10) 65% (±17) 100%70
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CB is an attractive source for unrelated transplantation of benign
indications because of the potentially better availability for minori-
ties. Since most patients are children, cell dosage is less of a limita-
tion; however, cell dose is still important. We have consistently
employed 3 strategies to maximize cell dose - plasma depletion pro-
cessing without red blood cell reduction, no post-thaw wash (NW),
and the use of double cords (2X) when necessary. A retrospective
CIBMTR-audited analysis was performed on all 87 pediatric
(\50 kg) patients with non-malignant disorders transplanted with
98 PD CB products (15 double cords) at 21 US and 16 international
institutions. Weight was used instead of age to emphasize impor-
tance of cell dose. The disease breakdowns were: 40 thalassemias,
12 congenital immunodeficiency syndromes, 9 aplastic anemia, 5
Hurler syndrome, 4 osteopetrosis, 2 chronic granulomatous dis-
ease, 2 familial hemophagocytosis, 2 Fanconi anemia, 2 inherited
metabolic disorders, and 9 for other disorders. Transplant charac-
teristics: median age 4 years (range 0.1–27); median weight 16 kg
(range 4–49); male 54%; HLA ABDR matches: 18–6/6; 32–5/6;
30–4/6; 6–3/6, 1–2/6; median pre-freeze TNC dose 9.8  107/kg;
median post-thaw TNC dose as reported by TC 6.7  107/kg; me-
dian pre-freeze CD341 dose 3.5  105/kg; transplants outside of
U.S.- 54 (62%); non-myeloablative - 13 (15%); 34% post-thaw
washed (W) and 66% infused without post-thaw wash (NW) of
those with known post-thaw status. Median follow-up time was
220 days (range 8–1,448 days). With no unevaluable cases, cumula-
tive incidence was used to estimate engraftment, acute and chronic
graft-versus-host disease (aGvHD and cGvHD), and Kaplan-Meier
estimates were used for all other outcome. As shown below, forego-
ing post-thaw wash improved engraftment, TRM and survival, and
significantly reduced extensive cGvHD. This series is unusual in its
cell dose, high even for pediatric patients, and shows that unrelated
PD CB transplantation can be performed safely and effectively, with
outstanding neutrophil (92 6 9%) and platelet engraftment (85 6
9%), extensive cGvHD (3 6 3%), overall (90 6 4%) and disease-
free survival (78 6 6%) rates achieved when post-thaw wash is not
employed, even in a diverse population of pediatric patients with
non-malignant disorders.
